Key facts
- This page summarizes Joseph J. Larosa's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2026, 16:04.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Tax liability
Sale
Sale
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Footnote F2
Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Footnote F3
The stock option award vested in four equal annual installments, commencing one year after the date of grant.